IL4 and myeloid sarcoma: Previous clinical trials of MS patients treated with TSO demonstrated increased Th2-associated cytokines [124], increased Th2 cytokine interleukin-4 (IL4) producing and decreased IL2 producing T cells, mild elevation of peripheral eosinophil counts [125], and decreased active brain lesions [126].